Joost J Oppenheim

This inventor holds 9 USPTO granted patents and 1 published patent application, plus 1 CIPO patent. Top assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services. Active years: 2002-2022.

USPTO Granted Patents = 9 (Patent Applications = 1)

% Patents Active = 77.8

CIPO Patents = 1 (Patent Applications = 1)

Average Co-Inventor Count = 4.6

ph-index = 3

Forward Citations = 17(Granted Patents)

Location History:

Bethesda, MD (US) (2002 - 2022)
Rockville, MD (US) (2022)

Company Filing History:

9 out of 3,693

The United States of America, as Represented by the Secretary, Department of Health and Human Services

patents

Years Active: 2002-2022

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11389480 - Human monoclonal antibody targeting TNFR2 for cancer immunotherapy (2022-07-19),

2. 11266746 - Therapeutic antitumor combination of a TLR4 ligand with other treatments (2022-03-08),

3. 9567566 - HMGN polypeptides as immune enhancers and HMGN antagonists as immune suppressants (2017-02-14),

4. 8227417 - HMGN polypeptides as immune enhancers and HMGN antagonists as immune suppressants (2012-07-24),

5. 6830893 - T20/DP178 is an activator of human phagocyte formyl peptide receptors (2004-12-14),

6. 6808877 - Ligands for FPR class receptors that induce a host immune response to a pathogen or inhibit HIV infection (2004-10-26),

7. 6562859 - Ureido derivatives of poly-4-amino-2-carboxy-1-methyl pyrrole compounds for inhibition of inflammation (2003-05-13),

8. 6475741 - Neutrophil chemotactic factor cloned cDNA and monoclonal antibodies thereto (2002-11-05),

9. 6376659 - Nucleic acids encoding a novel neutrophil chemotactic factor (2002-04-23),

Title: Joost J Oppenheim: Innovator in Cancer Immunotherapy

Introduction

Joost J Oppenheim is a prominent inventor based in Bethesda, MD, known for his significant contributions to cancer immunotherapy. With a total of 9 patents, Oppenheim has made remarkable strides in the field of medical research, particularly in developing innovative therapeutic approaches.

Latest Patents

Oppenheim's latest patents include a human monoclonal antibody targeting tumor necrosis factor receptor 2 (TNFR2) for cancer immunotherapy. This antibody specifically binds to TNFR2 and promotes antibody-dependent cell-mediated cytotoxicity (ADCC) of human TNFR2CD4T regulatory cells in a dose- and time-dependent manner. Additionally, he has developed methods for using these TNFR2 antibodies in tumor immunotherapy. Another notable patent involves a therapeutic antitumor combination of a Toll-like receptor (TLR) 4 ligand with other treatments. This method enhances the immune-stimulating effect through the co-administration of TLR4 ligands and immune checkpoint inhibitors, providing a promising approach to cancer treatment.

Career Highlights

Oppenheim is affiliated with the National Institutes of Health, a component of the US Department of Health & Human Services. His work at this esteemed institution has allowed him to focus on groundbreaking research that has the potential to transform cancer treatment.

Collaborations

Throughout his career, Oppenheim has collaborated with notable colleagues, including De Yang and Michael Bustin. These partnerships have contributed to the advancement of his research and the development of innovative therapeutic strategies.

Conclusion

Joost J Oppenheim's contributions to cancer immunotherapy through his patents and research at the National Institutes of Health highlight his role as a leading inventor in the medical field. His work continues to pave the way for new treatment options for cancer patients.